Historical Stock Chart
2 Months : From Nov 2019 to Jan 2020
By Carlo Martuscelli
Novartis AG (NOVN.EB) said Monday that it will cease development of its investigational asthma drug fevipiprant following disappointing clinical data.
A pooled analysis of the Phase 3 Luster-1 and Luster-2 studies showed that the therapy didn't meet the clinical threshold in the reduction of moderate-to-severe asthma exacerbations when compared with placebo, the company said. The drug was, however, found safe, the Swiss drug maker said.
An analysis of safety and efficacy data from the two studies will be conducted, and details will be published at an upcoming medical conference, Novartis said.
Write to Carlo Martuscelli at firstname.lastname@example.org; @carlomartu
(END) Dow Jones Newswires
December 16, 2019 01:39 ET (06:39 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.